The Expression Changes of CX3CL1 and Interlukin-6 Genes During Remission Induction Therapy in Patients With Acute Myeloid Leukemia

  • Mahdiyar Iravani Saadi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran http://orcid.org/0000-0002-0104-4684
  • Mani Ramzi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Aliasghar Karimi 2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 3. Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran
  • Maryam Owjfard 4. Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mahmoud Torkamani 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Nadiya Kheradmand 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Ahmad Niknam 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Zahed Karimi 1. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mohammad Kazem Vakil 2. Non Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
  • Mohammad Hosein Yazdanpanah 2. Non Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
Keywords: CX3CL-1, IL-6, Remission Therapy, Acute Myeloid Leukemia

Abstract

Background: Acute Myeloid Leukemia syndrome (AML) is a hematologic malignancy which is due to clonal extensive proliferation of leukemic precursor cells and is rapidly fatal unless treated or response to chemotherapy. Cytogenetic findings have important role in prognosis and categorization of AML. The aim of this study was to investigate the expression changes in CX3CL1 and Interlukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study 69 patients (36 males, 33 female) with AML was selected from tertiary medical heath center. A quantitative polymerase chain reaction (PCR) was done for mRNA expression of CX3CL1 and IL-6genes before and after induction chemotherapy. To obtain expression changes in CX3CL1 and IL-6genes, we used 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 was significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: In conclusion, as we showed that chemotherapy significantly increase the expression of CX3CL1 and IL-6 which can be used as a prognostic factor of AML.

References

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.

https://doi.org/10.1182/blood-2009-07-235358

PMid:19880497

Ridgway D. The first 1000 dendritic cell vaccinees. Cancer investigation. 2003;21(6):873-86.

https://doi.org/10.1081/CNV-120025091

PMid:14735692

Estey EH, editor. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Seminars in hematology; 2006: Elsevier.

https://doi.org/10.1053/j.seminhematol.2006.01.002

PMid:16616042

Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Journal of clinical oncology. 2003;21(9):1874-81.

https://doi.org/10.1200/JCO.2003.09.113

PMid:12721266

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-95.

https://doi.org/10.1182/blood-2007-10-117671

PMid:18390837

Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells, Molecules, and Diseases. 2015;54(1):84-9.

https://doi.org/10.1016/j.bcmd.2014.07.015

PMid:25172541

Li K, Lv XX, Hua F, Lin H, Sun W, Cao WB et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll‐like receptor 2‐mediated cell‐penetrating peptide. International journal of cancer. 2014;134(3):692-702.

https://doi.org/10.1002/ijc.28382

PMid:23852533

Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cell‐penetrating peptides as a novel transdermal drug delivery system. Chemical biology & drug design. 2012;80(5):639-46.

https://doi.org/10.1111/cbdd.12008

PMid:22846609

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine. 2006;354(6):610-21.

https://doi.org/10.1056/NEJMra052723

PMid:16467548

Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. European Journal of Neuroscience. 2004;20(5):1150-60.

https://doi.org/10.1111/j.1460-9568.2004.03593.x

PMid:15341587

Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. Journal of leukocyte biology. 2012;92(1):51-8.

https://doi.org/10.1189/jlb.0112035

PMid:22457367

D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert opinion on therapeutic targets. 2010;14(2):207-19.

https://doi.org/10.1517/14728220903540265

PMid:20055718

Sugiyama H, Inoue K, Ogawa H, Yamagami T, Soma T, Miyake S et al. The expression of IL-6 and its related genes in acute leukemia. Leukemia & lymphoma. 1996;21(1-2):49-52.

https://doi.org/10.3109/10428199609067579

PMid:8907269

Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30(5):1128-33.

https://doi.org/10.1002/hep.510300522

PMid:10534331

Heinrich PC, Behrmann I, Serge H, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical journal. 2003;374(1):1-20.

https://doi.org/10.1042/bj20030407

PMid:12773095 PMCid:PMC1223585

Iravani Saadi M, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B, Ramzi M. Aberrant Expression of the miR-181b/miR-222 after Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2019;35(3):446-50. doi:10.1007/s12288-018-01066-6.

https://doi.org/10.1007/s12288-018-01066-6

PMid:31388255 PMCid:PMC6646491

SAADI MI, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B, Ramzi M. Up-Regulation of the miR-92a and miR-181a in Patients with Acute Myeloid Leukemia and their Inhibition with Locked Nucleic acid (LNA)-antimiRNA; Introducing c-Kit as a New Target Gene. International Journal of Hematology and Oncology.28(3):001-9.

Saadi MI, Beigi MAB, Ghavipishe M, Tahamtan M, Geramizadeh B, Zare A et al. The circulating level of interleukins 6 and 18 in ischemic and idiopathic dilated cardiomyopathy. Journal of cardiovascular and thoracic research. 2019;11(2):132.

https://doi.org/10.15171/jcvtr.2019.23

PMid:31384408 PMCid:PMC6669430

Ramzi M, Saadi MI, Yaghobi R, Arandi N. Dysregulated Expression of CD28 and CTLA-4 Molecules in Patients with Acute Myeloid Leukemia and Possible Association with Development of Graft versus Host Disease after Hematopoietic Stem Cell Transplantation. Int J Organ Transplant Med (IJOTM). 2019;10(2).

Saadi MI, Ramzi M, Hosseinzadeh M, Ebrahimi N, Owjfard M, Abdolyousefi EN et al. Expression Levels of Il-6 and Il-18 in Acute Myeloid Leukemia and Its Relation with Response to Therapy and Acute GvHD After Bone Marrow Transplantation. Indian Journal of Surgical Oncology. 2021. doi:10.1007/s13193-021-01358-w.

https://doi.org/10.1007/s13193-021-01358-w

PMid:34658572

Saadi MI, Bozorgi H, Ramzi M, Noshadi E, Akbari A, Haghighinejad ZK et al. Characterization of MiR-92b, 1275 and 551 in Patients with Acute Myeloid Leukemia and their association with acute Graft versus Ho Disease after Hematopoietic Stem cell Transplantation.

Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92(10):3943-8.

https://doi.org/10.1182/blood.V92.10.3943

PMid:9808588

Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Practice & Research Clinical Haematology. 2008;21(2):177-92.

https://doi.org/10.1016/j.beha.2008.02.006

PMid:18503985

Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen J, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26(12):2462.

https://doi.org/10.1038/leu.2012.135

PMid:22699419

Brissot E, Bossard C, Malard F, Braudeau Cc, Chevallier P, Guillaume T et al. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft‐versus‐host disease. Journal of leukocyte biology. 2015;97(2):227-35.

https://doi.org/10.1189/jlb.5HI0714-325R

PMid:25420917

Li H, Li J, Cheng J, Chen X, Zhou L, Li Z. AML‑derived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562‑ADM fusiform transformation and chemoresistance. Oncology reports. 2019;42(3):1035-46.

https://doi.org/10.3892/or.2019.7237

PMid:31322275 PMCid:PMC6667869

Devemy E, Li B, Tao M, Horvath E, Chopra H, Fisher L et al. Poor prognosis acute myelogenous leukemia: 3-biological and molecular biological changes during remission induction therapy. Leukemia research. 2001;25(9):783-91.

https://doi.org/10.1016/S0145-2126(01)00032-7

Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P et al. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. European Journal of Cancer. 2010;46(18):3383-92.

https://doi.org/10.1016/j.ejca.2010.07.022

PMid:20728344

Zeng Y, Jiang J, Huebener N, Wenkel J, Gaedicke G, Xiang R et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer letters. 2005;228(1-2):187-93.

https://doi.org/10.1016/j.canlet.2005.01.057

PMid:15953676

Published
2021-12-31
How to Cite
Iravani Saadi, M., Ramzi, M., Karimi, A., Owjfard, M., Torkamani, M., Kheradmand, N., Niknam, A., Karimi, Z., Vakil, M. K., & Yazdanpanah, M. H. (2021). The Expression Changes of CX3CL1 and Interlukin-6 Genes During Remission Induction Therapy in Patients With Acute Myeloid Leukemia. Galen Medical Journal, 10, e2288. https://doi.org/10.31661/gmj.v10i0.2288